Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Daren Lin

Showing results (11-20 of 20) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 20 results.
Scientific Reports|July 29, 2015
Randomized, Multicenter Study of Gefitinib Dose-escalation in Advanced Non-small-cell Lung Cancer Patients Achieved Stable Disease after One-month Gefitinib TreatmentCong Xue, Shaodong Hong, Ning Li, et al.
Cancer Communications (London, England)|January 18, 2025
Efficacy and safety of KN026 and docetaxel for HER2-positive breast cancer: a phase II clinical trialJianli Ma, Jingxuan Wang, Ting Xu, et al.
Drug Metabolism and Disposition: the Biological Fate of Chemicals|September 29, 2023
The Effects of Drug Exposure and Single Nucleotide Polymorphisms on Aaptinib-Induced Severe Toxicities in Solid TumorsYouhao Chen, Yaobin Lin, Shaoxing Guan, et al.
Gynecologic Oncology|October 24, 2024
Phase II study of enlonstobart (SG001), a novel PD-1 inhibitor in patients with PD-L1 positive recurrent/metastatic cervical cancerGuiling Li, Xiaofan Li, Rutie Yin, et al.
Cancer Letters|April 15, 2020
Downregulation of the circadian rhythm regulator HLF promotes multiple-organ distant metastases in non-small cell lung cancer through PPAR/NF-κb signalingJiarong Chen, Aibin Liu, Zhichao Lin, et al.
Leukemia|February 19, 2020
A proposal for a new staging system for extranodal natural killer T-cell lymphoma: a multicenter study from China and Asia Lymphoma Study GroupHuangming Hong, Yexiong Li, Soon Thye Lim, et al.
Signal Transduction and Targeted Therapy|May 21, 2026
Fulvestrant versus capecitabine as maintenance therapy in hormone receptor-positive, HER2-negative metastatic breast cancer after first-line chemotherapy (FAMILY): a multicenter, open-label, randomized, phase 3 trialWenjing Wu, Yaping Yang, Haizhu Chen, et al.
Lancet (London, England)|October 22, 2025
Izalontamab brengitecan, an EGFR and HER3 bispecific antibody-drug conjugate, versus chemotherapy in heavily pretreated recurrent or metastatic nasopharyngeal carcinoma: a multicentre, randomised, open-label, phase 3 study in ChinaYunpeng Yang, Huaqiang Zhou, Linquan Tang, et al.
Nature Medicine|July 11, 2024
Benmelstobart, anlotinib and chemotherapy in extensive-stage small-cell lung cancer: a randomized phase 3 trialYing Cheng, Jianhua Chen, Wei Zhang, et al.
Signal Transduction and Targeted Therapy|April 7, 2026
Anti-PD-1 antibody penpulimab plus chemotherapy for recurrent or metastatic nasopharyngeal carcinoma: a randomized, double-blind phase 3 studyShuang Huang, Feng Liu, Song Qu, et al.
Pageof 2

Showing results (11-20 of 20) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 20 results.
Scientific Reports|July 29, 2015
Randomized, Multicenter Study of Gefitinib Dose-escalation in Advanced Non-small-cell Lung Cancer Patients Achieved Stable Disease after One-month Gefitinib TreatmentCong Xue, Shaodong Hong, Ning Li, et al.
Cancer Communications (London, England)|January 18, 2025
Efficacy and safety of KN026 and docetaxel for HER2-positive breast cancer: a phase II clinical trialJianli Ma, Jingxuan Wang, Ting Xu, et al.
Drug Metabolism and Disposition: the Biological Fate of Chemicals|September 29, 2023
The Effects of Drug Exposure and Single Nucleotide Polymorphisms on Aaptinib-Induced Severe Toxicities in Solid TumorsYouhao Chen, Yaobin Lin, Shaoxing Guan, et al.
Gynecologic Oncology|October 24, 2024
Phase II study of enlonstobart (SG001), a novel PD-1 inhibitor in patients with PD-L1 positive recurrent/metastatic cervical cancerGuiling Li, Xiaofan Li, Rutie Yin, et al.
Cancer Letters|April 15, 2020
Downregulation of the circadian rhythm regulator HLF promotes multiple-organ distant metastases in non-small cell lung cancer through PPAR/NF-κb signalingJiarong Chen, Aibin Liu, Zhichao Lin, et al.
Leukemia|February 19, 2020
A proposal for a new staging system for extranodal natural killer T-cell lymphoma: a multicenter study from China and Asia Lymphoma Study GroupHuangming Hong, Yexiong Li, Soon Thye Lim, et al.
Signal Transduction and Targeted Therapy|May 21, 2026
Fulvestrant versus capecitabine as maintenance therapy in hormone receptor-positive, HER2-negative metastatic breast cancer after first-line chemotherapy (FAMILY): a multicenter, open-label, randomized, phase 3 trialWenjing Wu, Yaping Yang, Haizhu Chen, et al.
Lancet (London, England)|October 22, 2025
Izalontamab brengitecan, an EGFR and HER3 bispecific antibody-drug conjugate, versus chemotherapy in heavily pretreated recurrent or metastatic nasopharyngeal carcinoma: a multicentre, randomised, open-label, phase 3 study in ChinaYunpeng Yang, Huaqiang Zhou, Linquan Tang, et al.
Nature Medicine|July 11, 2024
Benmelstobart, anlotinib and chemotherapy in extensive-stage small-cell lung cancer: a randomized phase 3 trialYing Cheng, Jianhua Chen, Wei Zhang, et al.
Signal Transduction and Targeted Therapy|April 7, 2026
Anti-PD-1 antibody penpulimab plus chemotherapy for recurrent or metastatic nasopharyngeal carcinoma: a randomized, double-blind phase 3 studyShuang Huang, Feng Liu, Song Qu, et al.
Pageof 2